Is RKLB a buy, hold, or sell?
RKLB carries a valuation grade of Reduce. Our discounted cash flow model produces an intrinsic range of $49–$98 — implying a -11% margin of safety at the current price of $82.55. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 12% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 11.0% earnings surprise. Analyst estimate revisions are trending downward.
What are RKLB's key risk factors?
With a beta of 2.55, RKLB exhibits a highly aggressive risk profile relative to the broad market. The 95th-percentile CVaR of -46.4% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 4.6% of total portfolio loss in the worst 5% of months. Net margins of -26.9% fall below the Industrials sector average of 11%, suggesting margin pressure. The balance sheet is conservatively leveraged at 6% debt-to-equity.
At 0.71, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 70.4% exceeds realized volatility of 1.1% by 69 points, suggesting options are pricing in elevated risk. Insiders have been net sellers to the tune of $1060.5M recently. While routine dispositions are common, the magnitude bears watching. Short interest stands at 5.9% of float, a moderate level.
How does RKLB fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — RKLB carries a beta of 2.55, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all reduceings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, RKLB shows the strongest co-movement with LHX (0.33), GD (0.27), NOC (0.23). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all reduceings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The RKLB analysis here is a single node in that larger structure.
For the full transatlantic conviction hierarchy — including RKLB's position sizing, conviction rating, and upside/risk case in the 2026 defence supercycle — see: Defence Spending 2026: The Transatlantic Allocation Case →
